What is ADMA Biologics's ADMA bio manufacturing — D&A?

ADMA Biologics (ADMA) reported ADMA bio manufacturing — D&A of $1.28M in Q2 2026.

What is the long-term trend for ADMA Biologics's ADMA bio manufacturing — D&A?

Over 3 years (2021 to 2024), ADMA Biologics's ADMA bio manufacturing — D&A has grown at a -4.2% compound annual growth rate (CAGR), from $4.22M to $3.71M.

What does ADMA bio manufacturing — D&A mean?

Represents the systematic allocation of the cost of tangible and intangible assets over their useful lives within the manufacturing segment. It provides insight into the capital intensity of the segment's infrastructure and production facilities.

ADMA Biologics (ADMA) ADMA Bio Manufacturing — D&A

Screener

Other segment segments

Plasma Collection Centers

$499K—

Similar metrics at other companies

CWCOManufacturing Units — D&A

$26.67K+2.3%

AMPGManufacturing And Engineering — D&A

$314.62K+237%

GBXManufacturing — D&A

$21.5M+13.2%

TWINManufacturing — D&A

$2.9M-11.1%

RAILManufacturing — D&A

$1.5M+9.6%

CRLManufacturing — D&A

$7.39M-86.6%

Other financials

Income statement

See full

Revenue$124.4M+2.0%

Gross profit$86.3M+28.3%

Operating income$52.4M+22.5%

Net income$37.8M+10.5%

EPS (diluted)$0.16+14.3%

Balance sheet

See full

Cash & equivalents$136.0M+50.7%

Total debt$203.9M+1,855%

Total equity$408.2M+2.5%

Total assets$684.2M+22.5%

Cash flow

See full

Operating cash flow$29.5M+39.7%

CapEx$2.3M-6.9%

Free cash flow$27.3M+45.8%

Valuation

See full

Market cap$2.25B-49.1%

Enterprise value$2.32B-46.6%

P/E13.3×-7.9×

P/S4.4×-4.9×

Profitability

See full

Gross margin64.7%+11.7pp

Operating margin43.8%+11.0pp

Net margin33%-11.1pp

FCF margin22.7%+8.9pp

Returns & leverage

See full

Return on equity41.9%-29.3pp

Debt / equity0.5×+0.5×

Current ratio7×+1.6×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 5:16 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001140361-26-031445

(in thousands)	ADMA Bio Manufacturing	Plasma Collection Centers	Total
Plasma center operating expenses	-	1,026	1,026
Gain on sale of plasma centers	-	-	-
Selling, marketing and distribution	7,634	-	7,634
Depreciation and amortization expense	1,281	499	1,780
General and administrative expense	8,340	-	8,340
Other income (expense), net	(20)	150	130
Income (loss) before taxes	64,010	(707)	63,303
Expenditures for additions to long-lived assets	2,256	-	2,256

Item 1. Financial Statements.

FAQ

What is ADMA Biologics's ADMA bio manufacturing — D&A?: ADMA Biologics (ADMA) reported ADMA bio manufacturing — D&A of $1.28M in Q2 2026.
What is the long-term trend for ADMA Biologics's ADMA bio manufacturing — D&A?: Over 3 years (2021 to 2024), ADMA Biologics's ADMA bio manufacturing — D&A has grown at a -4.2% compound annual growth rate (CAGR), from $4.22M to $3.71M.
What does ADMA bio manufacturing — D&A mean?: Represents the systematic allocation of the cost of tangible and intangible assets over their useful lives within the manufacturing segment. It provides insight into the capital intensity of the segment's infrastructure and production facilities.